In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application

Cytotherapy

Volumn 14, Issue 4, 2012, Pages 451-460

  Brennig, Sebastian ^a   Rattmann, Ina ^a,b,c   Lachmann, Nico ^a   Schambach, Axel ^a   Williams, David A ^b,c   Moritz, Thomas ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

cytidine deaminase; cytosine arabinoside; hematotoxicity; in vivo selection

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CELL COMPARTMENTALIZATION; CELL POPULATION; CYTOTOXICITY; DNA MODIFICATION; ENRICHMENT CULTURE; FEMALE; HEMATOPOIETIC CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; THROMBOCYTOPOIESIS;

EID: 84863351766     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.646043     Document Type: Article

References (51)

1. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-3.
2. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Dewey RA, et al. Stem-cell gene therapy for the Wiskott - - Aldrich syndrome. N Engl J Med. 2010;363:1918-27.
3. Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodefi ciency. Int J Hematol. 2002;76:295-8. (Pubitemid 43014090)
4. O tt MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401-9.
5. Neff T, Beard BC, Kiem HP. Survival of the fi ttest: in vivo selection and stem cell gene therapy. Blood. 2006;107:1751-60. (Pubitemid 43289350)
6. Flasshove M, Moritz T, Bardenheuer W, Seeber S. Hematoprotection by transfer of drug-resistance genes. Acta Haematol. 2003;110:93-106. (Pubitemid 37340188)
7. Trobridge GD, Kiem HP. Large animal models of hematopoietic stem cell gene therapy. Gene Ther. 2010;17:939-48.
8. Moritz T, Williams DA. Marrow protection - transduction of hematopoietic cells with drug resistance genes. Cytotherapy. 2001;3:67-84. (Pubitemid 32466092)
9. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136-43. (Pubitemid 28468826)
10. Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME, et al. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood. 2004;103:796-803. (Pubitemid 38129535)
11. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J, et al. Effi cient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 2000;6:652-8. (Pubitemid 30398788)
12. Cowan KH, Moscow JA, Huang H, Zujewski JA, O ' Shaughnessy J, Sorrentino B, et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res. 1999; 5:1619-28. (Pubitemid 29334437)
13. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood. 1999;94:52-61. (Pubitemid 29300134)
14. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, Kiem HP. Effi cient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest. 2010;120:2345-54.
15. Larochelle A, Choi U, Shou Y, Naumann N, Loktionova NA, Clevenger JR, et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensifi cation in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest. 2009;119:1952-63.
16. Milsom MD, Williams DA. Live and let die: in vivo selection of gene-modifi ed hematopoietic stem cells via MGMTmediated chemoprotection. DNA Repair (Amst). 2007;6: 1210-21. (Pubitemid 47058403)
17. Jansen M, Sorg UR, Ragg S, Flasshove M, Seeber S, Williams DA, et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther. 2002;9:737-46. (Pubitemid 34971304)
18. Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose intensifi ed chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 2000;60:5187-95.
19. Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006;107:3010-1.
20. Schmitz N, Diehl V. Carmustine and the lungs. Lancet. 1997;349:1712-3. (Pubitemid 27252667)
21. Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia. 2005;19:2281-8. (Pubitemid 41741625)
22. Momparler RL, Eliopoulos N, Bovenzi V, Letourneau S, Greenbaum M, Cournoyer D. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fi broblast and hematopoietic cells. Cancer Gene Ther. 1996;3:331-8. (Pubitemid 126732454)
23. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol. 1996;24:1340-6. (Pubitemid 26348932)
24. Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, et al. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood. 2006;108:2965-71.
25. Eliopoulos N, Al-Khaldi A, Beausejour CM, Momparler RL, Momparler LF, Galipeau J. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modifi ed primary bone marrow stromal cells. Gene Ther. 2002;9:452-62. (Pubitemid 34428754)
26. Leach WB, Laster WR Jr, Mayo JG, Griswold DP Jr, Schabel FM Jr. Toxicity studies in mice treated with 1-beta- D - arabinofuranosylcytosine (ara-C). Cancer Res. 1969;29: 529-35.
27. Ubezio P, Tagliabue G, Schechter B, Agur Z. Increasing 1-beta- D -arabinofuranosylcytosine effi cacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Res. 1994;54:6446-51.
28. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DJ, et al. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood. 1992;79:2221-5.
29. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-21. (Pubitemid 40884400)
30. Randall TD, Weissman IL. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fl uorouracil treatment. Blood. 1997;89:3596-606. (Pubitemid 27227082)
31. Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci USA. 2010; 107:5551-6.
32. Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL, et al. Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia. 1989;3: 23-8. (Pubitemid 19022220)
33. Stentoft J. The toxicity of cytarabine. Drug Saf. 1990;5:7- 2 7.
34. Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv. 2010;7:1399-414.
35. Elli M, Aydin O, Bilge S, Bozkurt A, Dagdemir A, Pinarli FG, et al. Protective effect of vitamin A on ARA-C induced intestinal damage in mice. Tumori. 2009;95:87-90.
36. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/ granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA. 1997;94:1908-13. (Pubitemid 27113935)
37. Wilson A, Laurenti E, Oser G, Van der Wath RC, Blanco-Bose W, Jaworski M, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135:1118-29.
38. Bodine DM, Orlic D, Birkett NC, Seidel NE, Zsebo KM. Stem cell factor increases colony-forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in Sl/Sld mice as a single factor. Blood. 1992;79:913-9.
39. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904-8.
40. Van Pelt K, de Haan G, Vellenga E, Daenen SM. Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells. Exp Hematol. 2005;33:226-31. (Pubitemid 40164905)
41. Agur Z, Arnon R, Schechter B. Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Eur J Cancer. 1992;28A:1085-90.
42. Gardner RV, Lerner C, Astle CM, Harrison DE. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol. 1993;32:450-4. (Pubitemid 23234662)
43. (Pubitemid 351426178)
44. L uskey BD, Rosenblatt M, Zsebo K, Williams DA. Stem cell factor, interleukin-3, and interleukin-6 promote retroviral-mediated gene transfer into murine hematopoietic stem cells. Blood. 1992;80:396-402.
45. Ailles L, Schmidt M, Santoni de Sio FR, Glimm H, Cavalieri S, Bruno S, et al. Molecular evidence of lentiviral vectormediated gene transfer into human self-renewing, multipotent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther. 2002;6:615-26. (Pubitemid 35363694)
46. Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson BM, Thompson J, et al. Effi cient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood. 2004;103:3710-6. (Pubitemid 38596286)
47. Laufs S, Guenechea G, Gonzalez-Murillo A, Zsuzsanna Nagy K, Luz Lozano M, del Val C, et al. Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med. 2006;8:1197-207. (Pubitemid 44660519)
48. Sangiolo D, Lesnikova M, Nash RA, Jensen MC, Nikitine A, Kiem HP, et al. Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther. 2007;14:1549-54. (Pubitemid 47570715)
49. Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E. Genetically engineered T-cells expressing a ganciclovirsensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs. 2010;11:559-70.
50. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z, et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 2005;105:4235-46. (Pubitemid 40720768)
51. Weisburger EK. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer. 1977;40: 1935-49. (Pubitemid 8216970)